What is Generate Biomedicines, Inc. 's operating cash flow?

Generate Biomedicines, Inc. (GENB) reported operating cash flow of -$80.39M in Q1 2026.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Generate Biomedicines, Inc. GENB Operating Cash Flow

Operating Cash Flow at other companies

MYR GroupMYRG

$84.75M+1.8%

Piper SandlerPIPR

-$291.72M-40.8%

SSR MiningSSRM

$264.49M+221%

NNN REITNNN

$187.03M-8.0%

RepligenRGEN

$28.3M+88.6%

STU

StubHub Holdings, Inc.STUB

$298.42M+88.5%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's operating cash flow?: Generate Biomedicines, Inc. (GENB) reported operating cash flow of -$80.39M in Q1 2026.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.